Author
Denali Therapeutics (United States)ORCID 0000-0003-1325-0650Unclaimed ORCID profile · follow to get notified of new preprints
3 papers
Recent·Most cited
Oliver B. Davis, Jennifer E. Kung, Sonnet S. Davis…·Anastasia G. Henry
This study shows the PD-risk GBA1 variant E326K reduces lysosomal GCase activity by disrupting LIMP2 interaction and causes lysosomal and mitochondrial dysfunction.
Donna Marie Leippe, Rebeca M. Choy, Gediminas J. A. Vidugiris…·Jolanta Vidugirienė
The paper develops a bioluminescent assay to quantify cellular glycogen levels and validates its use in testing glycogen synthase inhibitors.
Annie Arguello, Cathal S. Mahon, Meredith Calvert…·Mihalis S. Kariolis
The paper compares brain delivery and efficacy of two TfR-targeted enzyme fusions in MPS II mice, finding the moderate-affinity ETV:IDS has better brain exposure and substrate reduction than the high-affinity IgG:IDS.